Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial

HM Earl, L Hiller, JA Dunn, C Blenkinsop, L Grybowicz, AL Vallier, I Gounaris, JE Abraham, L Hughes-Davies, K McAdam, S Chan, R Ahmad, T Hickish, D Rea, C Caldas, JMS Bartlett, DA Cameron, E Provenzano, J Thomas, RL Haywardfor the ARTemis Investigators Group, Luca Gianni

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial'. Together they form a unique fingerprint.

Medicine & Life Sciences